Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared With Standard Acei Therapies For Heart Failure Patients With Reduced Ejection Fraction In Taiwan
Heart failure (HF) is highly prevalent in the elderly people and has been considered as an intractable disease due to poor survival and life quality. Recently, a novel oral therapy, sacubitril/valsartan, has proven its efficacy in reducing cardiovascular (CV) mortality (by 20%) and all-cause mortality (by 16%) compared with enalapril, an angiotensin-converting enzyme inhibitor (ACEi) in HF patients with reduced ejection fraction (HFrEF). Taiwan has a universal health insurance program govern by a single payer, National Health Insurance Administration (NHIA).
Source: Value in Health - Category: International Medicine & Public Health Authors: C Fann, S Chen Source Type: research
More News: Cardiology | Cardiovascular | Diovan | Enalapril | Health Insurance | Heart | Heart Failure | Insurance | Taiwan Health